Sarepta Therapeutics, Inc. (SRPT) stock forecast & analysis
13.33
NasdaqGS · USDDelayed by 15 minutes
Down: -0.84, -5.9%
13.60Up: +0.27, +2.0%
1 analysis
Latest analysis: · verdict locked
- Open
- 13.93
- Previous close
- 14.17
- Day range
- 13.25 – 14.47
- 52-week range
- 13.25 – 24.68
- Volume (shares)
- 2.24M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 107.24M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 0.45
- Market cap
- 1.43B
Market Scanner’s AI analysis of Sarepta Therapeutics, Inc. (SRPT), updated November 2026: SRPT's recent analyses covered a bearish technical trend and a lack of company-specific news.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Sarepta Therapeutics, Inc. (SRPT) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
SRPT's recent analyses covered a bearish technical trend and a lack of company-specific news.
Recent analyses for SRPT noted a significant price decline over the past 91 days, with the stock trading below its 50-day and 200-day SMAs. A death cross occurred around mid-November, indicating a negative long-term trend. The company reported trailing twelve months revenue of $1,956.3M and a slight operating loss, with a small net income. No company-specific news was identified in the past week.
SRPT news & sentiment
Recent news coverage for SRPT was sparse, with no company-specific headlines identified in the past week. Social media discussion was not covered in the provided notes.
SRPT technical picture
SRPT's price action showed a significant decline over 7, 30, and 91 days, trading well below its 50-day and 200-day SMAs. A death cross occurred, with the 200-day SMA still sloping downward, indicating a negative long-term trend.
Fundamentals
The company reported trailing twelve months revenue of $1,956.3M. Operating income was approximately -$8.4M, resulting in an operating margin of about -0.4%. Trailing twelve months net income was approximately +$14.8M, yielding a net margin of about +0.8%.
Factors discussed — risks
- Price decline of 17.1% over 7 days and 28.2% over 30 days.
- Stock price below 50-day and 200-day SMAs.
- Death cross occurred mid-November, indicating a negative long-term trend.
- 200-day SMA is still sloping down.
- No company-specific news identified in the past week.
- technical trend
- momentum
- financials
- news coverage
Summary updated .
SRPT technical indicators
Common technical indicators for SRPT, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 17.90 | Price below |
| 10-day exponential moving average | 15.27 | Price below |
| Relative strength index (14-day) | 25.36 | Oversold |
| MACD line (12/26/9) | -1.1209 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 13.38 – 20.59 | Price below the lower band |
Analyses
Recent SRPT.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-21 SRPT.US analysis
Get the verdict — free
Frequently asked questions
- What are the risks for Sarepta Therapeutics, Inc.?
- Recent analyses noted a significant price decline, with the stock trading below key moving averages and experiencing a death cross, indicating a negative long-term trend. The company reported a slight operating loss for the trailing twelve months, and no company-specific news was identified in the past week.
- Is Sarepta Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Sarepta Therapeutics, Inc. examined factors on both sides. Discussed risks: Recent analyses noted a significant price decline, with the stock trading below key moving averages and experiencing a death cross, indicating a negative long-term trend. The company reported a slight operating loss for the trailing twelve months, and no company-specific news was identified in the past week. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Sarepta Therapeutics, Inc.?
- Recent news coverage for SRPT was sparse, with no company-specific headlines identified in the past week. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Sarepta Therapeutics, Inc.?
- Every analysis of Sarepta Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What are the risks for Sarepta Therapeutics, Inc.?
Recent analyses noted a significant price decline, with the stock trading below key moving averages and experiencing a death cross, indicating a negative long-term trend. The company reported a slight operating loss for the trailing twelve months, and no company-specific news was identified in the past week.
Is Sarepta Therapeutics, Inc. bullish or bearish?
Recent AI analyses of Sarepta Therapeutics, Inc. examined factors on both sides. Discussed risks: Recent analyses noted a significant price decline, with the stock trading below key moving averages and experiencing a death cross, indicating a negative long-term trend. The company reported a slight operating loss for the trailing twelve months, and no company-specific news was identified in the past week. These are descriptive observations, not a recommendation.
What is the latest sentiment on Sarepta Therapeutics, Inc.?
Recent news coverage for SRPT was sparse, with no company-specific headlines identified in the past week. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Sarepta Therapeutics, Inc.?
Every analysis of Sarepta Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- claude-medium-v2
Run a fresh SRPT.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.